Systematic review of a marine nutriceutical supplement in clinical trials for arthritis: the effectiveness of the New Zealand green-lipped mussel Perna canaliculus
- 933 Downloads
Nutritional supplements, such as Seatone, which contain freeze-dried tissue from the New Zealand green-lipped mussel Perna canaliculus, are sold in many countries to relieve arthritic symptoms and to aid in the regeneration of arthritic and injured joints.
Searches for all published controlled trials on the clinical effectiveness of green-lipped mussel, as a nutritional supplement with potential health benefits for arthritis, were carried out from four independent databases. No language restrictions were imposed, and the review was undertaken from extracted data and was assessed critically according to predefined criteria by the authors.
Reports of clinical studies, using freeze-dried mussel powder, show mixed outcome measures and are not conclusive, with only two of five randomized controlled trials attesting benefits for rheumatoid and osteoarthritis patients. Similarly, animal studies have likewise yielded mixed findings. In both these cases possibly due to the lack of stabilization of the omega-3 polyunsaturated fatty acids, now known to be the basis of anti-inflammatory activity.
There is little consistent and compelling evidence, to date, in the therapeutic use of freeze-dried green-lipped mussel powder products for rheumatoid or osteoarthritis treatment, particularly in comparison to other cheaper alternative nutriceutical supplements of proven efficacy. However, further investigations are necessary to determine whether green-lipped mussel supplements, such as Seatone, are therapeutic options in the management of arthritis.
KeywordsGreen-lipped mussel Nutritional supplement Osteoarthritis Perna canaliculus Rheumatoid arthritis Seatone
C. S. C. was supported by a research fellowship from The Boots Company, Nottingham, UK.
- 1.Jeffs AG, Holland RC, Hooker SH, Hayden BJ (1999) Overview and bibliography of research on the greenshell mussel, Perna canaliculus from New Zealand water. J Shellfish Res 18:347–360Google Scholar
- 2.Croft JE (1980) Relief from arthritis: a safe and effective treatment from the ocean. Thorsons Publishers Ltd, Wellingborough, Northampton, UKGoogle Scholar
- 3.Billard H (1985) L'extrait de Perna canaliculus, la moule aux orles verts de nouvelle-zelande en rheumatologie (Extract of Perna canaliculus (New Zealand green-lipped mussel) in rheumatology). Gaz Méd 92:97–101Google Scholar
- 5.Morelli V, Naquin C, Weaver V (2003) Alternative therapies for traditional disease states: osteoarthritis. Am Fam Phys 67:339–344Google Scholar
- 9.Rainsford KD, Whitehouse MW (1980) Gastroprotective and anti-inflammatory properties of green lipped mussel (Perna canaliculus) preparation. Arzneim-Forsch 30:2128–2132Google Scholar
- 11.Palmer DG (1980) Anti-inflammatory effects of mussel extracts. N Z Med J 92:328Google Scholar
- 15.Bui L, Bierer TL (2001) Influence of green lipped mussels (Perna canaliculus) in alleviating signs of arthritis in dogs. Vet Ther 2:101–111Google Scholar
- 21.Sinclair AJ, Murphy KJ, Li D (2000) Marine lipids: overview “news insights and lipid composition of Lyprinol”. Allerg Immunol 32:261–271Google Scholar
- 22.Halpern GM (2000) Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol). Allerg Immunol 32:272–278Google Scholar
- 25.Huskisson EC, Scott J, Bryans R (1981) Seatone is ineffective in rheumatoid arthritis. Br Med J 282:1358–1359Google Scholar
- 28.Audeval B, Bouchacourt P (1986) Etude contrôlée, en double aveugle contre placebo, de l'extrait de moule Perna canaliculus (moule aux orles verts) dans la gonarthose (Double blind, placebo-controlled study of the mussel Perna canaliculus (New Zealand green-lipped mussel) in arthritis of the knee). La Gazette 93:111–116Google Scholar
- 32.Gibson RG, Gibson SLM (1981) Seatone in arthritis. Br Med J 282:1795Google Scholar
- 37.Kendall RV, Lawson JW, Hurley LA (2000) New research and a clinical report on the use of Perna canaliculus in the management of arthritis. Townsend Lett Dr Patients 204:98–111Google Scholar
- 38.Bucci LR (1994) Chondroprotective agents: glucosamine salts and chondroitin sulphates. Townsend Lett Dr 1:52–54Google Scholar